Evidence map›Paper›PMID 37303048›Full record

ArticleDiagnostic pathology2023

A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.

Ivana Stružinská, Nikola Hájková, Jan Hojný, Eva Krkavcová, Romana Michálková, Jiří Dvořák, Kristýna Němejcová, Radoslav Matěj, Jan Laco, Jana Drozenová and 9 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Uterine leiomyoma with RAD51B::NUDT3 fusion: a report of 2 cases.Virchows Archiv : an international journal of pathology · 2024
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Ivana StružinskáDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ivana.struzinska@vfn.cz.ORCID http://orcid.org/0000-0002-8451-4222
Nikola HájkováDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Jan HojnýDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Eva KrkavcováDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Romana MichálkováDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Jiří DvořákDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Kristýna NěmejcováDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Radoslav MatějDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Jan LacoThe Fingerland Department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University, University Hospital Hradec Kralove, Prague, Czech Republic.
Jana DrozenováDepartment of Pathology, Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, 3rd, Czech Republic.
Pavel FabianDepartment of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Jitka HausnerováDepartment of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
Gábor MéhesDepartment of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary.
Petr ŠkapaDepartment of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Marián ŠvajdlerŠikl's Department of Pathology, The Faculty of Medicine, Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
David CibulaGynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic.
Filip FrühaufGynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic.
Michaela Kendall BártůDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Pavel DundrDepartment of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. pavel.dundr@vfn.cz.ORCID http://orcid.org/0000-0002-8940-6124
Charles University · CZMasaryk Memorial Cancer Institute · CZMasaryk University · CZUniversity of Debrecen · HU

Funding

European Regional Development Fund BBMRI_CZ LM2023033Ministerstvo Zdravotnictví Ceské Republiky NV19-03-00007
6 · The paper itself

Abstract

backgroundMolecular aberrations occurring in primary ovarian clear cell carcinoma (OCCC) can be of diagnostic, predictive, and prognostic significance. However, a complex molecular study including genomic and transcriptomic analysis of large number of OCCC has been lacking.

methods113 pathologically confirmed primary OCCCs were analyzed using capture DNA NGS (100 cases; 727 solid cancer related genes) and RNA-Seq (105 cases; 147 genes) in order to describe spectra and frequency of genomic and transcriptomic alterations, as well as their prognostic and predictive significance.

resultsThe most frequent mutations were detected in genes ARID1A, PIK3CA, TERTp, KRAS, TP53, ATM, PPP2R1A, NF1, PTEN, and POLE (51,47,27,18,13,10,7,6,6, and 4%, respectively). TMB-High cases were detected in 9% of cases. Cases with POLE

conclusionsThe current work has elucidated the complex genomic and transcriptomic molecular hallmarks of primary OCCCs. Our results confirmed the favorable outcomes of POLE

Indexed as

Adenocarcinoma, Clear CellNeoplasm Recurrence, LocalGene Expression ProfilingGene FusionGenomicsHumansCapture DNA NGSPOLE mutationRare ovarian tumorsRNA-Seq

Identifiers

PMID37303048
PMCPMC10259037
OpenAlexW4380290697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.